<DOC>
	<DOCNO>NCT01910519</DOCNO>
	<brief_summary>This study compare different immune response Influenza A ( H5N1 ) Virus Monovalent Vaccine without AS03 adjuvant . The Influenza A ( H5N1 ) Virus Monovalent Vaccine AS03 adjuvant vaccine approve use adult protect flu cause A/H5N1 `` bird flu '' virus Europe none vaccine use study approve use United States . The result study help researcher learn good way vaccinate people H5N1 flu .</brief_summary>
	<brief_title>Systems Biology Influenza A ( H5N1 ) Virus Monovalent Vaccine With Without Adjuvant System 03 ( AS03 )</brief_title>
	<detailed_description>The influenza virus ( germ ) cause influenza `` flu . '' The flu infection breathe tubes lung . In recent year , flu virus first infect bird begin infect human . One strain call avian influenza ( A/H5N1 subtype ) `` bird flu '' . Although human case bird flu diagnose United States , strain cause severe illness death several hundred people since late 2003. . Vaccination effective way control flu prevent illness complication . Vaccines help prevent illness cause body make antibody fight infection . One way improve effectiveness vaccine include substance stimulate immune system make antibody . This type substance call adjuvant ; one type adjuvant call AS03 ( Adjuvant System 03 ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals good health ( determine vital sign , medical history , physical examination laboratory test ) ; Able understand give informed consent ; Women childbearing potential must agree practice adequate contraception 1 month prior study entry day 100 study . Personal family history sleep disorder include follow : Narcolepsy without cataplexy ; Idiopathic Hypersomnia excessive daytime sleepiness unknown origin ; Sleep paralysis ; Sleep relate hallucination ( hypnagogic hypnopompic hallucination ) ; Human leukocyte antigen ( HLA ) DQB1*06:02 positivity ( DQB1*06 positivity high resolution HLA test perform ) ; An abnormal erythrocyte sedimentation rate baseline ; Receipt blood product 3 month prior study entry day 100 study ; Volunteers donate blood 56 day screen plan donate day 100 study ; Hemoglobin value le 12 mg/dL female less 13 mg/dL male ; A positive result Narcolepsy Mini Screen questionnaire ; A score ≥11 Epworth sleepiness scale questionnaire ; Receipt experimental agent within 6 week prior first vaccination completion study ; Receipt license live vaccine within 4 week license inactivated vaccine within 2 week prior first study vaccination plan receipt vaccine within 42 day study entry ; Receipt H5 vaccine AS03adjuvanted vaccine time past prior current study history A/H5N1 infection ; Influenzalike illness ( ILI ) document influenza infection 20132014 influenza season . [ Not exclude study , volunteer prior upper respiratory infection ILI ] ; Chronic medical problem include ( limited ) insulin dependent diabetes , severe heart disease , severe lung disease , severe liver disease , severe kidney disease , autoimmune disease , severe gastrointestinal disease ; Alcohol drug abuse psychiatric condition opinion investigator would preclude compliance trial interpretation safety endpoint data ; Impaired immune function chronic infection include ( limited ) HIV , hepatitis B C ; organ transplant ; active cancer history hematologic cancer ; receipt chemotherapy , radiation therapy ( past 36 month ) potentially immunosuppressive therapy [ i.e . Systemic steroid dose intraarticular administration steroid past 3 month ; ( Nasal topical steroid allow ) ] , congenital immunodeficiency , anatomical functional asplenia ; Heart rate le 40 bpm great 100 bpm . Systolic blood pressure le 90 mm Hg equal great 160 mm Hg . Diastolic blood pressure le 60 mm Hg equal great 100 mg Hg ; Pregnancy postpartum ( less 1 year delivery ) breast feeding ; Severe reaction prior vaccination influenza virus vaccine , include anaphylaxis ; History GuillainBarré syndrome ; A previous sudden lifethreatening allergic reaction ingredient Influenza A ( H5N1 ) Virus Monovalent Vaccine without AS03 adjuvant substance may present trace amount thiomersal , egg residue include ovalbumin well residual amount sodium deoxycholate detergent , formaldehyde sucrose ; Volunteers acute illness , include fever ( &gt; 100.4 F [ &gt; 38.0 C ] , regardless route ) within 3 day prior study entry ; Social , occupational , condition opinion investigator might interfere compliance study vaccine evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>influenza A ( H5N1 ) virus</keyword>
	<keyword>H5N1 influenza</keyword>
	<keyword>influenza A/H5/N1</keyword>
	<keyword>monovalent H5N1 influenza vaccine</keyword>
	<keyword>system biology</keyword>
	<keyword>AS03 adjuvant</keyword>
	<keyword>unadjuvanted</keyword>
</DOC>